Abstract: β-glucans are derived from a variety of sources including yeast, grain and fungus and belong to the class of drugs known as biological response modifiers. They possess a broad spectrum of biological activities that enhance immunity in humans. One promising area for β-glucans’ application is dermatology, including wound care. Topical applications of β-glucans are increasing, especially due to their pluripotent properties. Macrophages, keratinocytes and fibroblasts are considered the main target cells of β-glucans during wound healing. β-glucans enhance wound repair by increasing the infiltration of macrophages, which stimulates tissue granulation, collagen deposition and reepithelialization. β-glucan wound dressings represent a suitable wound healing agent, with great stability and resistance to wound proteases. This review summarizes the current knowledge and progress made on characterizing β-glucans’ wound healing properties in vitro and in vivo and their safety and efficacy in managing non-healing wounds or other chronic dermatological conditions and diseases.

Keywords: polysaccharide; natural product; immunomodulator; wound repair

1. Introduction

β-Glucans, which are glucose polymers, from a variety of sources including yeast, grain and fungus, belong to the class of drugs known as biological response modifiers [1]. Numerous studies have shown that β-D-glucans, either particulate or soluble, enhance immune functions with anti-infective, antitumor and immunomodulatory activity [2–6]. Additionally, they have extensive treatment applications in healthcare, not only for humans, but also invertebrates, rodents, fish and domestic farm animals due to their marked capability of modulating the immune system (reviewed in [7]). All β-glucans are glucose polymers linked by 1,3; 1,4 or 1,6 β-glycosidic bonds and differ from each other by their length and branching structure. The biological actions of the different β-glucans vary according to their molecular structure, solubility and the conformation of each polymer [8].

The mechanism of β-glucan action in the organism is mediated by several receptors, especially the Dectin-1 receptor, Toll-like receptors (TLR-2, 4, 6), complement receptor 3 (CR3), scavenger receptor and lactosylceramide [9]. The most important is the Dectin-1 receptor, which is highly expressed in many immunocompetent cells such as dendritic cells (DC), neutrophils, eosinophils, macrophages, monocytes, several T lymphocytes and also in cutaneous cells (keratinocytes and fibroblasts). After binding to the Dectin-1 receptor, β-glucan stimulates the production of many cytokines or activates other immune and non-immune reaction mechanisms [10].

One promising area of β-glucan application is dermatology, including wound care. Topical application of β-glucans is increasing, since their pluripotent activity (antioxidant, anti-inflammatory
and regenerative effects, immunomodulation, radioprotection, moisturization and rejuvenation) might help as a complementary therapy in managing various skin diseases and conditions [11–13]. In addition, some β-glucans also possess anti-infective properties and exhibit potential antibacterial activity against a broad spectrum of Gram-positive and Gram-negative bacteria [14]. β-Glucans may therefore represent a suitable wound healing agent with great stability and a broad range of biological activities.

Wound healing is a complex process involving various cellular and extracellular matrix components and cells (keratinocytes, fibroblasts, endothelial cells, mast cells, nerve cells and leucocyte subtypes) that participate differently in the three overlapping phases (inflammation, cell proliferation and tissue remodeling) [15]. As mentioned above, the recognition of and response to β-glucans are mediated primarily by cell surface receptors, including those from immunocytes and cutaneous cells. In terms of β-glucan immunostimulatory activity regarding wound healing, two modes of action are possible. One manifests by indirect activation through various cytokines of macrophages and the other by direct influence on keratinocytes and fibroblasts. When released, the range of growth factors from activated macrophages supports cellular proliferation, angiogenesis, reepithelialization and an increase in wound tensile strength [16]. A schematic depiction of the β-glucan pluripotent mechanisms of action is shown in Figure 1.

Figure 1. Schematic depiction of β-glucan pluripotent mechanisms in wound healing.
This review summarizes the current knowledge and progress made on characterizing β-glucan wound healing properties in vitro and in vivo and their safety and efficacy in managing non-healing wounds and burns.

2. Wound Healing Activity of β-Glucans: In Vitro Experiments

β-Glucans have been shown to possess interesting biological properties, including anti-inflammatory and immunomodulatory activity that could be effectively employed in the wound healing process. It has been proposed that β-glucans accelerate the healing process in both chronic and acute wounds [17]. Chronic wounds are characterized by a prolonged inflammatory phase where macrophages in granulation tissue, after stimulation with β-glucans, act as a source of growth factors and inflammatory cytokines (IL-6, IL-1β and TNFα), this pro-inflammatory event being mediated by the Dectin-1 receptor [18]. In another experiment, it was verified that macrophages can also stimulate other cells such as keratinocytes and fibroblasts that reepithelialize the wound and create granulation tissue [19,20].

β-Glucans also exhibited in vitro antimicrobial activity [21–23], directly against a broad range of bacterial species, including *Escherichia coli*, *Pseudomonas aeruginosa* and *Staphylococcus aureus*, or indirectly by enhancing macrophage phagocytic activity and resistance to bacterial challenge [24,25]. In another study, β-glucan from oats also showed antimicrobial effects against *Escherichia coli* and *Bacillus subtilis* [21]. Native β-glucans were able to partially (35% inhibition) inhibit the growth of these bacteria, while the cationic β-glucan caused 80% inhibition in both types of bacteria, indicating that β-glucan amination enhanced the antimicrobial effects. The antibacterial action mechanism of aminated oat β-glucans can be explained by the interaction of polycations with the negatively-charged bacterial surface, which alters membrane permeability and thereby inhibits growth. Thus, β-glucans, particularly derivatized ones, may inhibit the bacterial growth of wound pathogens and prevent biofilm formation in chronic wounds [21].

The in vitro wound healing properties of β-glucans have been well described, and most studies have been performed using cutaneous cells (fibroblasts and keratinocytes). Overall, β-glucans with different molecular weights, origins and physical and chemical characteristics were shown to be potent inducers of wound closure in vitro, significantly affecting the migration and proliferation of cells involved in wound repair. The major properties of β-glucan wound healing are summarized in Table 1.
Table 1. β-Glucan in vitro wound healing properties.

| Type of β-Glucan/Source | Structure of β-Glucan | Target Cell Type | Actions | Ref. |
|-------------------------|-----------------------|-----------------|---------|-----|
| W-S Curdlan, (7%)/Agrobacterium sp. | Linear (1,3,1,6) β-glucan | Swiss-3T3 fibroblast cells | Fibroblasts exposed to a curdlan/polyvinyl alcohol (PVA) blend showed significantly higher spreading rates in the scratch wound assay after 24 h when compared to control and pure PVA. | [26] |
| W-INS (2%)/Saccharomyces cerevisiae | Linear (1,3) β-glucan | 3T3 fibroblast cells, HaCaTs | β-glucan-based nanofibrilous membranes promoted the adhesion and proliferation of fibroblasts and keratinocytes. | [27] |
| W-S (2.5%)/Aureobasidium pullulans | Branched (1,3,1,6) β-glucan | Human fetal dermal fibroblast cell line FW20-2, primary human dermal fibroblasts | β-glucan consistently stimulated dermal fibroblast proliferation and migration and modulated the effect of transforming growth factor-β1, β-glucan l did not affect the procollagen production from fibroblasts. | [28] |
| W-S (0.75%)/Bradyrhizobium japonicum | Cyclic (1,3,1,6) β-glucan | Swiss-3T3 fibroblast cells | Cyclic β-glucan incorporated in hydrogels increased hydrogel porosity and enhanced cell attachment, proliferation and migration activity. | [29] |
| W-S Curdlan, (10 µg/mL)/Alcaligenes faecalis | Linear (1,3) β-glucan | Primary human keratinocytes | Curdlan enhanced migration, proliferation and wound closure of primary human keratinocytes in a Dectin-1 concentration-dependent manner. | [30] |
| W-S Laminarin (0.2 mg/mL)/Laminaria sp. | Linear (1,3) β-glucan with (1,6)-linked β-glucosyl | Immortalized human corneal epithelial cells | Both β-glucan types promoted epithelial migration in a concentration-dependent manner. This effect was enhanced when β-glucan was conjugated with hyaluronic acid to increase solubility. | [31] |
| W-S (1 mg/mL)/Saccharomyces cerevisiae | Branched (1,3,1,6) β-glucan | Human and mouse wound macrophages | β-glucan potently induced TNF-α production in wound macrophages via activation of the Dectin-1 and TLR2 signaling pathways. Interestingly, it also induced phosphorylation of the macrophage-colony stimulating factor. | [32] |
| W-INS, W-S (1 µg/mL)/various sources | Linear (1,3,1,4) β-glucan with (1,3,1,6) β-glucan | HaCaTs, 3T3-Li preadipocytes | β-glucares of different origin, solubility and purity were tested for inhibition of adipogenic differentiation, wound healing and skin irritation. Significant differences in efficacy between β-glucan preparations were shown. The most active was yeast-derived insoluble β-glucan. | [33] |
| W-S (1 mg/mL)/Aureobasidium pullulans | Branched (1,3,1,6) β-glucan | Primary human keratinocytes | β-glucan enhanced wound healing by enhancing fibroblast migration and collagen synthesis via glucan receptors on fibroblasts, as well as by activating macrophages to release more TNF-α. | [34] |
| W-INS Pleuran, (0.2 mg/mL)/Pleurotus ostreatus | Branched (1,3,1,6) β-glucan | Mouse macrophage cell line RAW264.7, human dermal fibroblasts | β-glucan treatment of L-929 cells resulted in a dose-dependent increase in cell proliferation. No significant difference in the migration speed between the glucan-treated and non-treated cell was documented. | [35] |
| W-S (0.5 and 5 mg/mL)/Lentinula edodes | Linear (1,3) β-glucan with (1,6)-linked β-glucosyl | Mouse connective tissue L-929 cells | β-glucan accelerated wound healing by enhancing fibroblast migration and collage synthesis via glucan receptors on fibroblasts, as well as by activating macrophages to release more TNF-α. | [36] |
Table 1. Cont.

| Type of β-Glucan/Source | Structure of β-Glucan | Target Cell Type | Actions | Ref. |
|-------------------------|-----------------------|-----------------|---------|-----|
| W-S (1 µg/mL)/Saccharomyces cerevisiae | Branched (1,3;1,6) β-glucan | Human dermal fibroblasts | Derivatized β-glucan increased nuclear factor-1 binding capacity and stimulated collagen biosynthesis in human dermal fibroblasts. | [19] |
| W-S (1 µg/mL)/Saccharomyces cerevisiae | Branched (1,3;1,6) β-glucan | Normal human dermal fibroblasts | Derivatized β-glucan stimulated the expression of cytokine and procollagen genes through the transcription factors activator protein-1 and specificity protein-1 in normal human dermal fibroblasts. It also stimulated expression of various growth factors participating in wound repair. | [37] |
| W-S (1 mg/mL)/Saccharomyces cerevisiae | Branched (1,3;1,6) β-glucan | Normal human dermal fibroblasts | β-glucan stimulated fibroblast NF-kB nuclear binding activity and interleukin 6 gene expression in a time-dependent manner. It can directly modulate the functional activity of human dermal fibroblasts. At least two binding sites for β-glucan on fibroblasts were identified. | [38] |
| W-S (0.01%)/Saccharomyces cerevisiae | Branched (1,3;1,6) β-glucan | Porcine keratinocytes | Carboxymethyl β-glucan at a concentration of 0.005 and 0.01% stimulated keratinocytes proliferation within 120 h of incubation in culture media. | [39] |

Note: W-INS, water-insoluble; W-S, water-soluble.
3. Wound Healing Activity of β-Glucans: Animal Studies

The findings of laboratory studies have provided compelling evidence that β-glucans can accelerate the wound healing process and inhibit the growth of pathogenic bacteria. Many research groups have therefore started paying attention to the topical application of β-glucans and explaining its wound healing contribution by stimulating the tissue regeneration, collagen deposition and reepithelialization and increasing wound tensile strength. Animal studies have been performed with different model organisms such as rats, mice and aquatic organisms (carp and trout) (see Table 2).

To evaluate the role of β-glucans in wound healing pre-clinical studies, only in vivo studies indexed in the Scopus and PubMed databases were considered. Based on this approach, 17 were identified and included in Table 2: eight of the studies involved a mouse wound model; seven used a rat wound model; and two were conducted using a carp and trout model.

Overall, β-glucan preparations or membranes/hydrogels incorporated with β-glucans with different solubility and origin were shown to be effective wound healing agents in all animal pre-clinical studies. In some cases, β-glucan was administrated both topically and systematically. The majority of the studies investigated the wound healing effect of β-glucan in an excised sterile wound model, and only one study [40] demonstrated the healing potential of β-glucan in an infected wound model. Contrary to some in vitro studies, in which a direct antibacterial effect of β-glucan was demonstrated, no evidence of the β-glucan antibacterial effect in in vivo studies is available.
Table 2. β-Glucan in vivo wound healing properties.

| Type of β-Glucan/Source | Structure of β-glucan | Animal Model               | Actions                                                                                                                                                                                                 | Ref. |
|-------------------------|-----------------------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| W-INS (4%)/Schizophyllum commune | Branched (1,3,1,6) β-glucan | Sprague-Dawley rat | Hydrogels incorporating β-glucan and sterilized with gamma radiation accelerated wound repair while releasing of β-glucan molecules from the hydrogel.                                                      | [41] |
| W-INS (2%)/Saccharomyces cerevisiae | Linear (1,3) β-glucan | Kunming mouse             | β-glucan-based nanofibrous membranes significantly reduced wound size compared to control groups. On Day 14, 83% wound size reduction was observed (26% in the control group). All wounds were completely covered with epidermis by Day 14, but the β-glucan group exhibited substantially more epithelialization. | [27] |
| W-S (0.75%)/Bradyrhizobium japonicum | Cyclic (1,3) β-glucan | Wistar rat                | Nanofibrous asymmetric membranes containing β-glucan significantly accelerated wound healing by promoting reepithelialization, tissue remodeling and collagen deposition. Collagen deposition was more organized than in the control group. The levels of pro-inflammatory cytokines at Day 8 were significantly lower in the β-glucan group compared to the control group. | [29] |
| W-S (0.1 mg/L)/Saccharomyces cerevisiae | Branched (1,3,1,6) β-glucan | Rainbow trout             | Wound healing progressed, at least partially, due to a low temperature of about 8.5 °C: β-glucan was shown to have a very limited effect on wound healing in trout, when in a bath. Complete healing was achieved only by Day 100.     | [42] |
| W-S (2.5%)/Aureobasidium pullulans | Branched (1,3,1,6) β-glucan | Diabetic C57BL/KsJ-db/db mouse | Treatment with β-glucan caused a significant decrease in wound size compared to the vehicle control (distilled water). Increased inflammatory cells in the granulation tissues of wound areas were also significantly less compared to the vehicle control, showing increased numbers of micro-vessels and fibroblasts, as well as reepithelialization. | [43] |
| W-S Laminarin (0.2 mg/mL)/Laminaria sp. | Linear (1,3) β-glucan with (1,6)-linked β-glucosyl Linear (1,3) β-glucan | Sprague-Dawley rat | β-glucan and β-glucan conjugated with hyaluronic acid suppressed acute inflammatory reactions in the rat corneal alkali burn model. Decreased corneal edema and less polymorphonuclear leukocytes infiltrates were observed in the β-glucan-treated wound. | [31] |
| W-S MacroGrad, (0.1 μg/mL)/Saccharomyces cerevisiae | Branched (1,3,1,6) β-glucan | Cyprinus carpio L. (carp) | β-glucan promoted the wound healing process in common carp compared to the group treated with 6.3 kDa oat fiber and the control fish group. The positive effect of the β-glucan preparation was related to the high branching levels due to fish being bathed in β-glucan-supplemented water, showing a higher wound closure ratio compared to a 6.3-kDa-supplemented bath. | [44] |
| W-S (1 mg/mL)/Sparassis crispa | Branched (1,3,1,6) β-glucan | ICR mouse                | Fungal β-glucan significantly increased the rate of wound healing due to, at least partially, local stimulation of collagen synthesis.                                                                      | [45] |
| W-S (2.5%)/Aureobasidium pullulans | Branched (1,3,1,6) β-glucan | ICR nu/nu mouse          | β-glucan promoted wound healing of full-thickness wounds infected by *S. aureus*, *S. pyogenes* and *P. aeruginosa*. β-glucan did not show any direct antibacterial activity, though it was able to heal the wounds.       | [40] |
| W-S (50%)/Aureobasidium pullulans | Branched (1,3,1,6) β-glucan | BALB/c nude mouse        | Poly-(lactic-co-glycolic acid) (PLGA), a constituent of the membranes containing 50% β-glucan, enhanced the wound’s interaction with the surrounding cells, proliferation and angiogenesis compared to the ones from the membranes without PLGA. A PLGA membrane with incorporated β-glucan may be applied as a skin substitute to accelerate wound healing. | [46] |
| Type of β-Glucan/Source | Structure of β-glucan | Animal Model | Actions | Ref. |
|-------------------------|-----------------------|--------------|---------|-----|
| W-S Curdlan, (11.1 mg/mL)/ *Alcaligenes faecalis* | Linear (1,3) β-glucan | Diabetic C57Bl/KsBom-db/db | β-glucan exerted its primary effects in the early phase of wound healing and was coherent with an effect on macrophage functions in the wound. A higher dosage frequency showed a significant improvement in wound closure compared to a low dosage frequency. | [47] |
| W-S (1%)/ *Aureobasidium pullulans* | Branched (1,3;1,6) β-glucan | ddY mouse | A β-glucan and chitosan complex was used for wound healing. The complex sheet did not dissolve during the application period, did not adhere to the wound and was easy to remove. The complex accelerated wound repair by activating macrophages and cytokines' release and accelerated reepithelialization of the skin wound. | [48] |
| W-INS Imuneks, (5% cream or 50 mg/kg)/ *Saccharomyces cerevisiae* | Branched (1,3;1,6) β-glucan | Wistar rat | Systemic and local administration of β-glucan stimulated wound contraction, increased incision tensile strength and improved epithelialization. Systemic administration was more effective than topical administration. | [49] |
| W-INS/Aureobasidium pullulans | Branched (1,3;1,6) β-glucan | Wistar rat | An aqueous mixture of β-glucan and polyvinyl alcohol increased the wound contraction ratio by 83% after 11 days, while when treating with cotton gauze, an 85% contraction was observed, but only after 21 days. Additionally, healing time was significantly reduced by 48% using the β-glucan mixture. The accelerating effect of wound healing might be attributed to the release of β-glucan. | [50] |
| W-S Curdlan, (11.1 mg/mL)/ *Alcaligenes faecalis* | Linear (1,3) β-glucan | Diabetic/ non-diabetic C57Bl/KsBom mouse | Significantly higher wound closure rates were observed in diabetic mice given topical applications of β-glucan compared to the placebo-treated mice. A more cell-rich and vascularized granulation tissue and an increase in the reepithelialization were observed. | [51] |
| W-S Betafectin, (2 mg/kg i.v.)/ *Saccharomyces cerevisiae* | Branched (1,3;1,6) β-glucan | Fisher-344 rat | Systemic β-glucan treatment resulted in enhanced migration of neutrophils to the site of inflammation and improved antimicrobial function. Polymorphonuclear cells obtained from β-glucan-treated animals showed a heightened respiratory burst and a reduced bacterial load in a pulmonary model of infection. | [52] |
| Imuneks (100 mg/kg p.o.)/ *Saccharomyces cerevisiae* | Branched (1,3;1,6) β-glucan | Sprague-Dawley rat | An oral administration of β-glucan improved impaired anastomatic wound healing in rats treated with corticosteroids over a long period of time. Increased macrophages and fibroblast population were observed in samples from β-d-glucan-treated animals. | [53] |

Note: W-INS, water-insoluble; W-S, water-soluble; i.v., intravenous; p.o., per oral.
4. Clinical Evidence for the Use of β-Glucans in the Management of Human Non-Healing Wounds and Burns

Despite the abundance of published data on in vitro and in vivo β-glucan effects in wound healing, to date, only a few human clinical studies have been conducted utilizing β-glucans in wound care management [54–57]. According to the web resource www.clinicaltrials.gov (date: 1 October 2018; terms: wound and glucan; conditions: all studies; country: all countries), two human randomized clinical studies with an estimated number of participants of 80 per trial are currently in progress focusing on the treatment of diabetic foot ulcers and venous leg ulcers using β-glucan-based products.

The first human study, in which the authors evaluated the effectiveness of a β-glucan cream (containing pleuran from Pleurotus ostreatus) as a topical treatment for venous ulcers, was published in the proceedings of a scientific meeting [58], followed by another study published in 2012 [54]. In this non-randomized trial with intragroup comparisons over time, water-insoluble (1→3)-β-glucan isolated from Saccharomyces cerevisiae was applied in the form of a cream with a final concentration of 3% (w/w) directly onto the ulcer bed of 12 patients [54]. This procedure was performed daily for up to 90 days. The authors documented that the average percentage of reduction of an ulcer was 11.3% after 30 days of treatment and 55.23% after 90 days. Insoluble β-glucan has been shown to enhance venous ulcer healing and increase epithelial hyperplasia, as well as increase plasmocyte and fibroblast proliferation.

In fact, four human clinical studies involving less than 90 participants provided evidence that β-glucan can accelerate the wound healing of chronic wounds (Table 3). Two of these clinical studies used water-insoluble β-glucan [54,57], and two other studies used water-soluble β-glucan [55,56]. Only one clinical study [55] represented a double blind, placebo-controlled trial.

In the case of burn injuries, a β-glucan collagen matrix was used as a primary wound dressing to treat pediatric partial thickness burns in 43 patients [59]. The β-glucan dressing reduced the pain, improved wound healing and had excellent cosmetic results in 79% of patients. The authors did not document any adverse effects during β-glucan treatment.

The treatment of chronic wounds is protracted and intensive and associated with high costs. Various approaches have been developed to treat chronic wounds, including topical wound-care therapies. The major arguments for employing natural products are the low cost and absence of antimicrobial resistance risk compared to conventional wound-care products. In a very recent study [60], Cutting evaluated the economic benefits of a β-glucan gel in the treatment of diabetic foot ulcers using a Markov cohort simulation model. The analysis revealed cost savings over an annual budget cycle of £GBP 503.00 per patient. Additionally, β-glucan gel was able to heal 94% of wounds compared to 78% from the ones of the standard care.

Generally, all the conducted human clinical studies suggest that β-glucan is an effective, safe, well-tolerated and economic wound dressing for the treatment of non-healing wounds and burns.
Table 3. Summary of data collection from human clinical studies using β-glucan as a topical remedy in the treatment of ulcers of different etiology.

| Type of β-Glucan (Source)/Placebo | Structure of β-Glucan | Ulcer Type     | No. of Participants β-Glucan/Placebo | Treatment Duration | Result                                                                                                               | Ref. |
|----------------------------------|-----------------------|----------------|--------------------------------------|--------------------|----------------------------------------------------------------------------------------------------------------------|------|
| 3% W-INS (*Saccharomyces cerevisiae*)/− | Linear (1,3) β-glucan | venous | 12/−                                 | 90 d               | A 55.2% reduction of the ulcer area was documented at the 90th day. β-glucan increased epithelial hyperplasia, as well as increased inflammatory cells, angiogenesis and fibroblast proliferation. | [54] |
| 2% W-S (*Saccharomyces cerevisiae*)/− methylcellulose | Branched (1,3;1,6) β-glucan | diabetic | 27/27                               | 12 w               | An 87% reduction of the ulcer was documented in the β-glucan group compared to a 56% reduction in the control group. No serious adverse effects in the β-glucan group were recorded. | [55] |
| W-S (*Saccharomyces cerevisiae*)/− | Branched (1,3;1,6) β-glucan | leg         | 26/−                                 | 12 w               | An average wound surface area reduction of 41% was observed; one wound healed; 20 decreased in size; four remained static; and two increased in size. | [56] |
| W-S (*Saccharomyces cerevisiae*)/− | Branched (1,3;1,6) β-glucan | diabetic | 22/−                                 | 20 w               | The time for complete healing averaged 10.8 weeks (range 6–20 weeks). No adverse effects were recorded during the treatment. | [57] |

Note: W-INS, water-insoluble; W-S, water-soluble; d, days; w, weeks.
5. Sterilization of β-Glucans and Their Impact on β-Glucan Bioactivity

Today, β-glucans represent effective topical agents for the treatment of chronic wounds and burns. However, licensed wound care products containing β-glucan must undergo a sterilization process. In fact, the most therapeutic compositions for clinical testing in humans are sterilized, and in many cases, sterilization is required to meet stringent regulations. Sterilization of β-glucan-based products is vital due to the presence of potential harmful contaminants, such as vegetative bacteria and microbial spores. However, some traditional sterilization techniques such as ethylene oxide and heat may have negative effects on chemical and physical properties and may thus alter β-glucan’s biological properties [61]. Some sterilization methods such as filtration are also time consuming and difficult to perform on polymeric viscous solutions. Therefore, some other means of sterilization have to be adopted, such as gamma irradiation.

**Gamma Irradiation**

Gamma irradiation, as well as X-ray and an electron beam may cause physical and chemical changes in the β-glucan structure. These techniques are being recognized as effective tools in lowering the molecular weight of β-glucans to enhance their solubility and permeability into the cells and to lessen viscosity. Gamma irradiation is a relatively simple method and leads to an increase in the functionality of β-glucans [62]. Several studies have investigated the effect of irradiating β-glucans on their biological and pharmacological properties [63–66]. Different gamma irradiation doses were used, starting from 2 up to 75 kGy. A significant decrease in the molecular weight of non-irradiated β-glucans has already been documented to occur at a low irradiation dose (8 kGy) [64]. Among the studied irradiation doses, 50 kGy proved to be an effective dose, allowing the maintenance of excellent antioxidant and functional properties. Further, the physical properties (e.g., gel fraction, compressive strength) of irradiated β-glucans were enhanced by increasing the irradiation dose [41]. Taken together, irradiated β-glucan exhibits: (a) a higher antimicrobial activity compared to the native samples; (b) an enhanced antioxidant, antitumor and antiproliferative activity; and finally, (c) an enhanced response in the immune system, suggesting that smaller molecules of irradiated β-glucans have a higher chance of binding to a receptor.

Gamma irradiation has successfully been used in preparing fabricated β-glucan hydrogels for wound dressings [41]. In this study, Gwon et al. verified that the irradiated hydrogels stimulated wound repair in an animal wound model; therefore, irradiated β-glucan may be considered a good tissue regeneration agent with strengthened wound healing properties.

6. Conclusions

In vivo studies and human clinical trials have provided compelling evidence that β-glucan preparations including hydrogels and nanofibers with incorporated β-glucan molecules promote moist wound healing and repair mainly due to the activation of the immune and cutaneous cells. β-glucans can induce the proliferation and migration of keratinocytes and fibroblasts through specific receptors such as Dectin-1, CR3 or TLRs. The direct antibacterial properties of β-glucans remain controversial as they have not been demonstrated in vivo. However, it was proposed that activation of wound macrophages and antigen-presenting cells by β-glucan represents a potential mechanism in eradicating bacterial load from chronic wounds.

Besides therapeutic benefits, treating chronic wounds with β-glucan hydrogels can help with reducing healing time and the total costs per treatment, but additional human clinical studies are needed to prove the efficacy of β-glucan-based wound dressings in treating a broad spectrum of chronic wounds and burns.

**Acknowledgments:** The study was supported by the project Center for Experimental and Clinical Respirology II (ITMS 26220120034), co-financed by EU sources.
Author Contributions: Both authors (J.M. and M.J.) participated in the writing of the article and approved the final version.

Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; nor in the decision to publish the results.

References

1. Bohn, J.A.; BeMiller, J.N. (1→3)-b-D-Glucans as biological response modifiers: A review of structure-functional relationships. Carbohydr. Polym. 1995, 28, 3–14. [CrossRef]

2. Pretus, H.A.; Ensley, H.E.; McNamee, R.B.; Jones, E.L.; Browder, I.W.; Williams, D.L. Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan. J. Pharmacol. Exp. Ther. 1991, 257, 500–510. [PubMed]

3. Williams, J.D.; Mueller, A.; Browder, W. Glucan-based macrophage stimulators. A review of their anti-infective potential. Clin. Immunother. 1996, 5, 392–399. [CrossRef]

4. Browder, W.; Williams, D.; Pretus, H.; Olivero, G.; Enrichens, F.; Mao, P.; Franchello, A. Beneficial effect of enhanced macrophage function in trauma patient. Ann. Surg. 1990, 211, 605–613. [PubMed]

5. Sherwood, E.R.; Williams, D.L.; DiLuzio, N.R. Glucan stimulates production of antitumor cytolitic/cytostatic factor(s) by macrophages. J. Biol. Response Mod. 1986, 5, 504–526. [PubMed]

6. Sherwood, E.R.; Williams, D.; McNamee, R.B.; Jones, E.L.; Browder, I.W.; DiLuzio, N.R. In vitro tumoricidal activity of resting and glucan-activated Kupffer cells. J. Leukoc. Biol. 1987, 42, 69–75. [CrossRef] [PubMed]

7. Stier, H.; Ebbeskotte, V.; Gruenwald, J. Immune-modulatory effects of dietary Yeast Beta-1,3/1,6-D-glucan. Nutr. J. 2014, 13, 1–9. [CrossRef] [PubMed]

8. Wang, Q.; Sheng, X.; Shi, A.; Hu, H.; Yang, Y.; Liu, L.; Fei, L.; Liu, H. β-Glucans: Relationships between modification, conformation and functional activities. Molecules 2017, 22, 257. [CrossRef] [PubMed]

9. Bloebaum, R.M.; Grant, J.A.; Sur, S. The future of allergy and asthma treatment. Int. Rev. Allergy Clin. Immunol. 2004, 4, 63–67. [CrossRef] [PubMed]

10. Sun, L.; Zhao, Y. The biological role of dectin-1 in immune response. Int. Rev. Immunol. 2007, 26, 349–364. [CrossRef] [PubMed]

11. Kanlayavattanakul, M.; Lourith, N. Carboxymethylglucan in cosmetics. Thai Pharm. Health Sci. J. 2008, 3, 378–382.

12. Gautier, S.; Xhaufillaire-Uhoda, E.; Gorry, P.; Pierard, G.E. Chitin-glucan, a natural cell scaffold for skin moisturization and rejuvenation. Int. J. Cosmet. Sci. 2008, 30, 459–469. [CrossRef] [PubMed]

13. Jesenák, M.; Urbancék, M.; Majtan, J.; Banovcin, P.; Hercogova, J. β-Glucan-based cream (containing pleuran isolated from Pleurotus ostreatus) in supportive treatment of mild-to-moderate atopic dermatitis. J. Dermatol. Treat. 2016, 27, 351–354. [CrossRef] [PubMed]

14. Jantova, S.; Bakos, D.; Birosova, L.; Matejov, P. Biological properties of a novel coladerm-beta glucan membrane. In vitro assessment using human fibroblasts. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc 2015, 159, 67–76.

15. Singer, A.J.; Clark, R.A. Cutaneous wound healing. N. E. J. Med. 1999, 341, 738–746. [CrossRef] [PubMed]

16. Falanga, V. Growth factors and wound healing. J. Dermatol. Surg. Oncol. 1993, 19, 711–714. [CrossRef] [PubMed]

17. Davis, S.C.; Perez, R. Cosmeceuticals and natural products: Wound healing. Clin. Dermatol. 2009, 27, 502–506. [CrossRef] [PubMed]

18. Lundahl, M.L.E.; Scanlan, E.M.; Lavelle, E.C. Therapeutic potential of carbohydrates as regulators of macrophage activation. Biochem. Pharmacol. 2017, 146, 23–41. [CrossRef] [PubMed]

19. Wei, D.; Zhang, L.; Williams, D.L.; Browder, W. Glucan stimulates human dermal fibroblast collagen biosynthesis through a nuclear factor-1 dependent mechanism. Wound Repair Regen. 2002, 10, 161–168. [CrossRef] [PubMed]

20. Son, H.J.; Han, D.-W.; Baek, H.S.; Lim, H.R.; Lee, M.H.; Woo, Y.I.; Park, J.-C. Stimulated TNF-alpha release in macrophage and enhanced migration of dermal fibroblast by β-glucan. Curr. Appl. Phys. 2007, 7 (Suppl. 1), 33–36. [CrossRef]
21. Shin, M.S.; Lee, S.; Lee, K.Y.; Lee, H.G. Structural and biological characterization of aminated-derivatized oat beta-glucan. J. Agric. Food Chem. 2005, 53, 5554–5558. [CrossRef] [PubMed]

22. Chамиđah, A.; Hardoko; Prihanto, A.A.; American Institute of Physics. Antibacterial activities of β-glucan (laminaran) against gram-negative and grampositive bacteria. AIP Conf. Proc. 2017, 1844, 020011. [CrossRef]

23. Chinnu, K.; Mathukumaran, M.; Mukund, S.; Sivasubramanian, V. Antimicrobial and antifungal activity of isolated betaglucan from chroococcus turgidus. Indian J. Pharm. Sci. Res. 2014, 4, 217–220.

24. Estrada, A.; Yun, C.H.; Van Kessel, A.; Li, B.; Hauta, S.; Laarveld, B. Immunomodulatory activities of oat beta-glucan in vitro and in vivo. Microbiol. Immunol. 1997, 41, 991–998. [CrossRef] [PubMed]

25. Hetland, G.; Ohno, N.; Aaberge, I.S.; Lovik, M. Protective effect of beta-glucan against systemic Streptococcus pneumoniae infection in mice. FEMS Immunol. Med. Microbiol. 2000, 27, 111–116. [PubMed]

26. Basha, R.Y.; Sampath Kumar, T.S.; Doble, M. Electrospun nanofibers of curdlan (β-1,3 glucan) blend as a potential skin scaffold material. Macromol. Mater. Eng. 2017, 302, 1600417. [CrossRef]

27. Wu, C.; Chen, T.; Xin, Y.; Zhang, Z.; Ren, Z.; Lei, J.; Chu, B.; Wang, Y.; Tang, S. Nanofibrous asymmetric membranes self-organized from chemically heterogeneous electrospun mats for skin tissue engineering. Biomed. Mater. 2016, 11, 035019. [CrossRef] [PubMed]

28. Choi, J.-S.; Kim, J.W.; Jung, G.-W.; Moon, S.-B.; Cho, H.-R.; Sung, S.H.; Jung, J.J.; Kwon, Y.S.; Ku, S.K.; Sohn, J.-H. Effect of a β-glucan from Aureobasidium on TGF-β1-modulated in vitro dermal wound repair. Toxicol. Environ. Health Sci. 2016, 8, 12–18. [CrossRef]

29. Nair, A.V.; Raman, M.; Doble, M. Cyclic β-(1→3) (1→6) glucan/carrageenan hydrogels for wound healing applications. RSC Adv. 2016, 6, 98545–98553. [CrossRef]

30. Van den Berg, L.M.; Zijlstra-Willems, E.M.; Richters, C.D.; Ulrich, M.M.W.; Geijtenbeek, T.B.H. Dectin-1 activation induces proliferation and migration of human keratinocytes enhancing wound re-epithelialization. Cell. Immunol. 2014, 289, 49–54. [CrossRef] [PubMed]

31. Choi, J.A.; Oh, T.-H.; Choi, J.-S.; Chang, D.-J.; Joo, C.-K. Impact of β,1-3-glucan isolated from Euglena gracilis on corneal epithelial cell migration and on wound healing in a rat alkali burn model. Curr. Eye Res. 2013, 38, 1207–1213. [CrossRef] [PubMed]

32. Roy, S.; Dickerson, R.; Khanna, S.; Collard, E.; Gnyawali, U.; Gordillo, G.M.; Sen, C.K. Particulate β-glucan induces TNF-α production in wound macrophages via a redox-sensitive NF-κβ-dependent pathway. Wound Repair Regen. 2011, 19, 411–419. [CrossRef] [PubMed]

33. Vetticka, V.; Vetticková, J. β (1-3)-D-glucan affects adipogenesis, wound healing and inflammation. Orient. Pharm. Exp. Med. 2011, 11, 169–175. [CrossRef]

34. Woo, Y.I.; Park, B.J.; Kim, H.-L.; Lee, M.H.; Kim, J.; Yang, Y.-I.; Kim, J.K.; Tsubaki, K.; Han, D.-W.; Park, J.-C. The biological activities of (1,3)-(1,6)-β-D-glucan and porous electrospun PLGA membranes containing β-glucan in human dermal fibroblasts and adipose tissue-derived stem cells. Biomed. Mater. 2010, 5, 044109. [CrossRef] [PubMed]

35. Majtan, J.; Kumar, P.; Koller, J.; Dragunova, J.; Gabrizz, J. Induction of metalloprotease 9 secretion from human keratinocytes by pleuran (β-glucan from Pleurotus ostreatus). Z. Naturforsch. C Biosci. 2009, 64, 597–600. [CrossRef] [PubMed]

36. Son, H.J.; Bae, H.C.; Kim, H.J.; Lee, D.H.; Han, D.-W.; Park, J.-C. Effects of β-glucan on proliferation and migration of fibroblasts. Curr. Appl. Phys. 2005, 5, 468–471. [CrossRef]

37. Wei, D.; Williams, D.; Browder, W. Activation of AP-1 and SP1 correlates with wound growth factor gene expression in glucan-treated human fibroblasts. Int. Immunopharmacol. 2002, 2, 1163–1172. [CrossRef]

38. Kougias, P.; Wei, D.; Rice, P.J.; Ensley, H.E.; Kalbfleisch, J.; Williams, D.L.; Browder, I.W. Normal human fibroblasts express pattern recognition receptors for fungal (1→3)-Beta-d-glucans. Infect. Immun. 2001, 69, 3933–3938. [CrossRef] [PubMed]

39. Zulli, F.; Suter, F. Improving skin function with CM-glucan, a biological response modifier from yeast. Int. J. Cosmet. Sci. 1998, 20, 79–86. [CrossRef] [PubMed]

40. Lee, J.-W.; Kwon, Y.-S.; Jang, K.-H. Effect of β-glucan originated from Aureobasidium on infected dermal wound healing of the normal nude mouse. J. Vet. Clin. 2012, 29, 464–469.

41. Gwon, H.-J.; Ann, S.-J.; Jeong, J.-O.; Kim, S.-M.; Park, J.-S.; Jeong, S.I.; Nho, Y.C.; Lim, Y.-M. Preparation and characterization of radiation fabricated β-glucan Hydrogels for wound dressing. Polymer (Korea) 2017, 41, 586–891. [CrossRef]
42. Schmidt, J.G.; Andersen, E.W.; Erbøll, B.K.; Nielsen, M.E. Muscle wound healing in rainbow trout (Oncorhynchus mykiss). *Fish Shellfish Immunol.* 2016, 48, 273–284. [CrossRef] [PubMed]

43. Yun, S.; Ku, S.-K.; Kwon, Y.-S. Effect of β-glucan from *Aureobasidium* on dermal wound healing in diabetic C57BL/6j-db/db mouse model. *J. Biomed. Res.* 2015, 16, 140–145. [CrossRef]

44. Przybylska-Diaz, D.A.; Schmidt, J.G.; Vera-Jiménez, N.I.; Steinbagen, D.; Nielsen, M.E. β-glucan enriched bath directly stimulates the wound healing process in common carp (*Cyprinus carpio L.*). *Fish Shellfish Immunol.* 2013, 35, 998–1006. [CrossRef] [PubMed]

45. King, B.; Barrett, S.; Cutting, K.F. Clinical evaluation of a bioactive beta-glucan gel in the treatment of venous ulcer healing. *Int. J. Mol. Sci.* 2013, 14, 113–118. [CrossRef] [PubMed]

46. Berdal, M.; Appelbom, H.I.; Eikrem, J.H.; Lund, A.; Busund, L.-T.; Seljelid, R.; Jenssen, T. Aminated β-1,3-d-glucan has a dose-dependent effect on wound healing in diabetic db/db mice. *Wound Repair Regen.* 2011, 19, 579–587. [CrossRef] [PubMed]

47. Kofuji, K.; Huang, Y.; Tsubaki, K.; Kokido, F.; Nishikawa, K.; Isobe, T.; Murata, Y. Preparation and evaluation of a novel wound dressing sheet comprised of β-glucan-chitosan complex. *React. Funct. Polym.* 2010, 70, 784–789. [CrossRef]

48. Cerci, C.; Yildirim, M.; Ceyhan, M.; Bozkurt, S.; Doguc, D.; Gokicimen, A. The effects of topical and systemic beta-glucan administration on wound healing impaired by corticosteroids. *Wounds* 2008, 20, 341–346. [PubMed]

49. Huang, M.-H.; Yang, M.-C. Evaluation of glucan/poly(vinyl alcohol) blend wound dressing using rat models. *Int. J. Pharm.* 2008, 366, 38–46. [CrossRef] [PubMed]

50. Medeiros, S.D.; Cordeiro, S.L.; Cavalcanti, J.E.; Melchuna, K.M.; Lima, A.M.; Filho, I.A.; Medeiros, A.C.; Rocha, K.B.; Oliveira, E.M.; Faria, E.D.; et al. Effects of purified *Saccharomyces cerevisiae* (1→3)-β-glucan on venous ulcer healing. *Int. J. Mol. Sci.* 2012, 13, 8142–8158. [CrossRef] [PubMed]

51. Zykova, S.N.; Balanda, K.A.; Vorokhobina, N.V.; Kuznetsova, A.V.; Engstad, R.; Zykov, T.A. Macrophage stimulating agent soluble yeast β-1,3/1,6-glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo-controlled phase II study. *J. Diabetes Investig.* 2014, 5, 392–399. [CrossRef] [PubMed]

52. Karaslan, O.; Kankaya, Y.; Sungur, N.; Kocer, U.; Cuzdan, S.; Sahin, B.; Uysal, A. Case series of topical and orally administered β-glucan for the treatment of diabetic wounds: Clinical study. *J. Cutan. Med. Surg.* 2012, 16, 180–186. [CrossRef] [PubMed]

53. King, B.; Barrett, S.; Cutting, K.F. Clinical evaluation of a bioactive beta-glucan gel in the treatment of ‘hard-to-heal’ wounds. *J. Wound Care* 2017, 26, 58–63. [CrossRef] [PubMed]

54. Duckova, K.; Kucera, J.; Kuniak, L.; Augustin, J. Some results of preclinical and clinical evaluation of topical preparations containing glucan. In Proceedings of the 1st World Meeting APGI/APV, Budapest, Hungary, 9–11 May 1995; pp. 729–730. [CrossRef] [PubMed]

55. Delatte, S.J.; Evans, J.; Hebra, A.; Adamson, W.; Othersen, H.B.; Tagge, E.P. Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children. *J. Pediatr. Surg.* 2001, 36, 113–118. [CrossRef] [PubMed]

56. Cutting, K.F. The cost-effectiveness of a novel soluble beta-glucan gel. *J. Wound Care* 2017, 26, 228–234. [CrossRef] [PubMed]
61. Munarin, F.; Bozzini, S.; Visai, L.; Tanzi, M.C.; Petrini, P. Sterilization treatments on polysaccharides: Effects and side effects on pectin. Food Hydrocoll. 2013, 31, 74–84. [CrossRef]

62. Khan, A.A.; Gani, A.; Masoodi, F.A.; Amin, F.; Wani, I.A.; Khanday, F.A.; Gani, A. Structural, thermal, functional, antioxidant & antimicrobial properties of β-d-glucan extracted from baker’s yeast (Saccharomyces cerevisae)-Effect of γ-irradiation. Carbohydr. Polym. 2016, 140, 442–450. [PubMed]

63. El-Sonbaty, S.M.; Ismail, A.F.M.A.F.M.; Nabeel, A.I. Irradiated β-glucan enhances immune response to bacterial infection through CD4 and CD8 T-lymphocytes. Int. J. Radiat. Res. 2013, 11, 35–42.

64. Shah, A.; Ahmad, M.; Ashwar, B.A.; Gani, A.; Masoodi, F.A.; Wani, I.A.; Wani, S.M.; Gani, A. Effect of γ-irradiation on structure and nutraceutical potential of β-d-glucan from barley (Hordeum vulgare). Int. J. Biol. Macromol. 2015, 72, 1168–1175. [CrossRef] [PubMed]

65. Byun, E.-B.; Park, S.-H.; Jang, B.-S.; Sung, N.-Y.; Byun, E.-H. Gamma-irradiated β-glucan induces immunomodulation and anticancer activity through MAPK and NF-κB pathways. J. Sci. Food Agric. 2016, 96, 695–702. [CrossRef] [PubMed]

66. El-sonbaty, S.M.; Zahran, W.E.; Moawed, F.S.M.F.S.M. Gamma-irradiated β-glucan modulates signaling molecular targets of hepatocellular carcinoma in rats. Tumor Biol. 2017, 39, 1–10.

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).